Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received a consensus rating of “Buy” from the nine brokerages that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $43.11.

DYN has been the subject of several analyst reports. Morgan Stanley started coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price objective for the company. Chardan Capital boosted their price target on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, May 21st. Oppenheimer reiterated an “outperform” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research note on Monday, May 6th. Jefferies Financial Group raised their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Finally, HC Wainwright upped their price target on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, May 20th.

Insider Activity

In related news, COO Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $77,403.26. Following the completion of the sale, the chief operating officer now owns 154,062 shares of the company’s stock, valued at approximately $4,355,332.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Susanna Gatti High sold 2,738 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26. Following the transaction, the chief operating officer now owns 154,062 shares in the company, valued at $4,355,332.74. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Richard William Scalzo sold 1,590 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $30.23, for a total value of $48,065.70. Following the sale, the senior vice president now directly owns 115,105 shares of the company’s stock, valued at $3,479,624.15. The disclosure for this sale can be found here. Insiders have sold 202,133 shares of company stock valued at $6,500,387 over the last ninety days. 20.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its position in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Dyne Therapeutics by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after acquiring an additional 857 shares in the last quarter. Wetzel Investment Advisors Inc. acquired a new position in Dyne Therapeutics in the 1st quarter worth about $28,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 5.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,921 shares of the company’s stock worth $305,000 after purchasing an additional 1,199 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after buying an additional 1,291 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Trading Up 2.1 %

Shares of DYN opened at $43.07 on Friday. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of -10.85 and a beta of 1.07. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $45.46. The firm has a fifty day simple moving average of $37.42 and a 200 day simple moving average of $29.77.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.